STM2457 directly binds to the METTL3-METTL14 heterodimer, competitively inhibiting the binding site of SAM, thus blocking METTL3’s catalytic activity. This provides a distinct therapeutic window for drug-resistant leukemia. The gene discussed is METTL3; the disease is leukemia.